WO1997039735A1

WO1997039735A1 - Improved masking of liposomes from res recognition

Info

Publication number: WO1997039735A1
Application number: PCT/US1996/005699
Authority: WO
Inventors: John R. Lau; W. Blair Geho
Original assignee: Sdg, Inc.
Priority date: 1996-04-24
Filing date: 1996-04-24
Publication date: 1997-10-30
Also published as: AU5571196A; EP0918508A1

Abstract

A biochemical membrane encapsulated by neuraminic acid residue to mask the surface of the membrane from recognition and removal by the scavenging RES cells of the body.

Description

IMPROVED MASKING OF LIPOSOMES FROM RES RECOGNITION

Background of the Invention

Definitions

SIALIC ACID: An N-acyl derivative of neuraminic acid.

NEURAMINIC ACID: A synthetically-derived sialic acid. The Chemical Abstracts Index names for this molecule are: D-glycero-D-galacto-2-Nonulopyranosidonic acid, methyl 5-amino-3, 5-dideoxy-(9Cl) ; or D-glycero-D-galacto- Nonulopyranosidonic acid, methyl 5-amino-3, 5-dideoxy-(8Cl) . Another name for this molecule is Methoxyneuraminic Acid, or Beta-Methoxy Neuraminic Acid. As ordered by the applicant from Sigma Chemical Company, P.O. Box 14508, St. Louis, MO 63178, it is named Neuraminic Acid Beta-Methyl-Glycoside (pfs) , product number N 5380 (1992 Catalog) .

NEURAMINIDASE: An enzyme of the hydrolase class that is in blood and which catalyzes the hydrolysis of glucosidic linkages between a sialic acid residue and a hexose or hexosamine residue at the non-reducing terminal of oligosaccharides in glycoproteins, glycolipids and proteoglycans.

LIPOSOME: A spherical particle in an aqueous medium, formed by a lipid bilayer enclosing an aqueous compartment.

BACKGROUND OF THE INVENTION

Liposomes, also known as vesicles, have been designed to encapsulate a cargo of pharmacological agents useful for in vivo purposes such as the diagnosis and treatment of various diseases and conditions. These cargo-carrying liposomes have, experimentally, shown potential for being site-specific carrier systems for a variety of such agents. Agents so delivered to designated sites in vivo demonstrate significantly enhanced therapeutic indices. Concurrently, decrease in unwanted side effects and wasted portions of dosages is achieved. Agents not so couried spread to nonspecific and often undesirable areas of the body, and possibly cause side effects.

The advantages of the prior art in vivo carrier system have been offset, however, by the deleterious effects of the body's reticuloendothelial system (the "RES") , mainly the liver and spleen. The RES acts to screen the body's circulation. The RES will gradually scavenge from the circulation all material it considers foreign and unwanted. Liposomes have certain physical characteristics which render them susceptible to removal by the RES. Once recognized, liposomes, whether given a site-specific molecule for so-called "targeted" delivery or not, are quickly phagocytosed by the RES along with their cargo. This prior revolutionary carrier system has, until the present invention, and the processor invention of U.S. Patent 4,501,728, remained hampered by the RES, the body's own defense mechanism.

In said earlier invention, U.S. Patent 4,501,728, the sialic acid mechanism for RES avoidance was a system consisting essentially of a biochemical membrane having sialic acid residues that mask the surface membrane from recognition by the RES cells.

Despite the successful application of sialic acid residues to the liposome carrier system, liposomes so disguised from the RES were nevertheless eventually subject to enzymatic action of endogenous neuraminidase in the blood. Specifically, it was found that neuraminidase cleaves the chemical bond between sialic acid and its attached sugar (galactose) , thereby allowing the galactose (sugar) on the surface of the liposome to be recognized by the RES's Ashwell receptor of the liver.

Enzymatic removal of the sialic acid is time-dependent. Liposomes intended to circulate for longer periods of time in the vascular system or until attracted to a binding-site, are removed by the RES once the sialic acid mask is compromised or lost.

Along with finding a means to mask the liposome from the RES, it is generally an objective in the art of drug delivery to discover an appropriate site-specific binding molecule. Once discovered, the binding molecule can be incorporated into the liposome. Such masked liposome with its binding molecule, when introduced in vivo, will evade the RES and will carry a designated cargo to a predetermined binding site in the body. When delivered, the cargo is then released to perform its designated function.

SUMMARY OF THE INVENTION

This invention is embodied by the product of a procedure of applying to the external surface of a liposome carrier system, two types of substituent molecules. One such molecule masks the liposome from the RES and is selected from the class consisting of those chemicals which are classed biologically as synthetically- derived molecules that prevent phagocytosis by the body's RES and which cannot be degenerated and separated from the liposome by the action of circulating endogenous enzymes.

The other molecule is one which binds to or is bound by a specific site in the body and which is incorporated as part of the liposome carrier. The combined result of the liposome carrier with these two types of substituent molecules, is highly effective delivery of the liposome's therapeutic or diagnostic cargo to a specific body site, having evaded the body's RES.

It is an object of this invention to create a composition of matter for in vivo administration of therapeutic or diagnostic agents, comprising a lipid membrane structure in the form of a liposome or vesicle, a second component which is a syntheticallyderived molecule that prevents recognition of the liposome or vesicle by the RES and which cannot be cleaved from the liposome or vesicle by the action of endogenous enzymes, and a third component which is a molecule that binds the liposome or vesicle to a specific site in the body and which can be present for site-specific delivery or absent for non-specific delivery of the therapeutic or diagnostic agents in vivo.

This invention is the discovery that superior site- specific delivery of the liposome's cargo is obtained by the combined effect of using synthetically-derived RES- avoidance molecules that cannot be cleaved by circulating endogenous enzymes, with site-specific binding molecules that find or are found by a receptor at a desired site in the body.

This invention is also the discovery that superior systemic circulation of liposomes without site-specific delivery, can be achieved using the aforementioned synthetic masking molecules without the site-binding molecule component.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a representative of a branched glycoprotein that has sialic acid as the terminal units of the glycan chains.

Figure 2 represents B-methoxyneuraminic acid structure.

Figure 3 illustrates the first example of a synthetic pathway by which a non-hydrolyzable secondary amide bond can be created by using an amide linkage to connect the B-methoxyneuraminic acid conjugate to an appropriate bridging molecule.

Figure 4 illustrates another synthetic pathway by which a secondary amide linkage can be formed between B-methoxyneuraminic acid and photoactivatable biotin resulting in a biotin B-methoxyneuraminic acid conjugate that can be attached to a liposome using streptavidin and biotin phosphatidyl ethanol amine.

Figure 5 shows the third type of synthetic pathway which would result in a bond formation between B-methoxyneuraminic acid and 2-iminothiolane (Traut's Reagent) , resulting in yet another secondary amine bond that is not hydrolyzable by the circulating endogenous enzyme neuraminidase.

Figure 6A and 6B show another synthetic pathway for establishing a non-hydrolyzable bond between neuraminic acid and p-maleimido phenyl butyrate phosphatidyl ethanol amine through the formation of a thio ether bond.

Figure 7 is a graph showing the 2-hour effect of neuraminic acid on I.V. liposome distribution; and

Figure 8 is a graph showing the effect of neuraminic acid on ⁵¹Chromium radiation.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

This invention embodies a liposomal delivery system consisting essentially of a phospholipid membrane known commonly as vesicles, or liposomes (vesicles and liposomes, as used herein, mean the same thing) , with two types of substituent molecules incorporated in the membrane.

One such type of molecule is classed biologically as a synthetic molecule which masks the liposome from the body's RES and which cannot be cleaved from the liposome by circulating endogenous enzymes. The other type of molecule is one which binds to a specific site in the body. The combination allows delivery of a greatly enhanced index of therapeutic or diagnostic cargo to such specific body site.

In the alternative, for superior circulatory life of liposomes without site-specific delivery, the aforementioned site-specific binding molecule can be omitted. B-methoxyneuraminic acid, used herein as a synthetic liposome masking molecule, is used in this description as an example and is preferred because its use is consistent with data shown herein.

The first example set forth hereinafter, is a liposome with a permeable membrane, which is designed and synthesized to circulate in the blood for an extended per$od of time as a non-binding time-release drug delivery system.

The second example set forth hereinafter, is a liposome which, in addition to being masked by the incorporation of neuraminic acid or its biologically active derivatives onto the liposome membrane, is also invested with a site-binding molecule. The inclusion of a site-binding molecule along with the neuraminic acid masking agent, creates a liposome which delivers its cargo to an appropriate specific site of action such as a tumor, without the danger of being removed prematurely from the circulation by the RES.

It has been found, according to this invention, that the combination of masking plus a specific site-binding molecule, such as a monoclonal antibody for binding to tumor cells, produces a quantum step beyond the expected benefits.

Our former U.S. Patent No. 4,501,728 teaches and claims a means to use naturally-occurring sialic acid to avoid RES recognition. The structural formula for a glycoprotein with terminal sialic acid units is depicted in Figure 1. A glycosidic bond connects the sialic acid to the penultimate sugar, usually a galactose.

Use of naturally-occurring sialic acid residues to mask liposomes from the RES enables liposomes to carry therapeutic or diagnostic agents in vivo for extended periods of time. Much like red blood cells, which also have sialic acid residues that perform the same masking function, these liposomes circulate systemically, evading the RES. But like red blood cells, liposomes masked with naturally-occurring sialic acid residues are subject to the action of circulating endogenous enzymes such as neuraminidase, which cleaves the glycosidic bond of the sialic acid, exposing its penultimate sugar to RES recognition. The enzymatic cleavage of this glycosidic bond is by hydrolysis, and occurs at the bond indicated by reference character 10 of Figure 1.

Despite the fact that RES masking is effectively achieved using naturally-occurring sialic acid residues, it was discovered by the applicants that vastly improved masking-time can be achieved by using a synthetic sialic acid, such as the preferred Beta-methoxyneuramic acid, which cannot be cleaved and thus exposed to the RES by circulating endogenous enzymes. Therefore, the preferred best mode embodiment uses Beta-methoxyneuraminic acid, the systematic name of which is given above in the Definition section. See Figure 2. Note that the sugar of this molecule has a free primary amino group (-NH-) attached to carbon #5 of the nonulopyranose ring structure, along with a non-reactive B-methoxy group (OCH -) attached to carbon #2 of the ring.

The best mode product of this invention was found to be one in which the following was observed:

1) The bond of this invention is not susceptible to hydrolysis by the enzyme neuraminidase in the plasma of a warm blooded host;

2) The bond is stable both in vivo and in vitro for an indefinite period of time;

3) The bond can be of a secondary amine type;

4) The bond can be of a thio ether type;

6) The bond is not readily hydrolyzable by other circulating endogenous enzymes in the plasma.

Figure 3 illustrates the first example of a synthetic pathway by which a nonhydrolyzable secondary amide bond is created by using an amide linkage to connect the B-methoxyneuraminic acid sugar to an appropriate bridging molecule. Reference character 11 of Figure -3 points out the amide linkage (-C-N-) resulting in a secondary amine.

Figure 4, illustrates another synthetic pathway by which a secondary amide linkage is formed between B-methoxyneuraminic acid and photoactivatable biotin resulting in a biotin B-methoxyneuraminic acid conjugate that can be attached to 8 liposome using streptavidin and biotin phosphatidyl ethanol amine.

Figure 5, shows the third type of synthetic pathway resulting in a bond formation between B-methoxyneuraminic acid and 2-iminothiolane (Traut's Reagent) resulting in vet another secondary amine bond that is not hydrolyzable by the circulating endogenous enzyme neuraminidase. While all three examples illustrate the formation of a second amine bond, the -R- group to which the secondary amine is attached is different.

Figure 6A and Figure 6B show another synthetic pathway for establishing a non-hydrolyzable bond between neuraminic acid and p-maleimido phenyl butyrate phosphatidyl ethanol amine through the formation of a thio ether bond. In this synthetic pathway, the B-methoxy group is removed from B-methoxyneuraminic acid by HCl. The resulting neuraminic acid is acylated with acetic anhydride to form its fully acylated sugar derivative. This sugar derivative is then reacted with the halo acid hydrogen bromide to form the acetohalo saccharide. The acetohalo saccharide is then reacted with thiourea to form the thiourea acetate derivative, which, in turn, is reacted with potassium carbonate and sodium bisulfite to remove the acetyl groups in order to form the sulfhydryl sugar, 2-thioglycose. 2-thioglycose is reacted with sodium methoxide (a base) in the presence of methanol, to generate the thioneuraminic acid derivative. Since this neuraminic acid sugar has a free sulfhydryl, it reacts with the maleimido group of p-maleimido phenyl butyrate phosphatidyl ethanolamine, which, in turn, is coupled to the vesicle membrane. By establishing a provision in the aforementioned synthetic pathways for a non-hydrolyzable bond linking the B-methoxyneuraminic acid to the bridging molecule, the circulating half-life of the B-methoxyneuraminic acid-masked liposomes in a warm blooded host is significantly enhanced.

As an example of practicing this invention without using the site-binding molecule, insulin was administered in vivo as the cargo of a porous liposome which had attached to its phospholipid membrane only the synthetic masking molecule B-methoxyneuraminic acid. The liposome was found to circulate in the body for significantly extended periods of time, releasing insulin, because of the fact that the B-methoxyneuraminic acid's sugar group could not be hydrolyzed and separated from the liposome by the endogenous enzyme neuraminidase.

Figure 7 and 8, together with the following text, establish the exceptional performance of a liposomal delivery system consisting essentially of a phospholipid membrane with a B-methoxyneuraminic acid substituent, wherein said acid is attached to the liposome by a bond which is not hydrolyzed by a circulating endogenous enzyme such as neuraminidase in the blood of a warm blooded animal.

EXAMPLE #1 : AVOIDANCE OF LIVER AND SPLEEN IN RATS Liposomes were made with the following compositions:

1. DSL = Distearoyl Lecithin

2. DCP = Dicetyl phosphate

3. CHOL = Cholesterol

4. MPB-PE = p-maleimido phenyl butyrate phosphatidyl ethanol

The liposomes were made using the method described in U.S. Patent 4,603,044. Briefly, the crusts, having the above compositions, were solubilized with 10.0ml of lOmM PhosPhate buffer, PH 7.4, to which a lOul aliquot of ¹²³I-human growth hormone was added. The mixture was sonicated on a Heat Systems Branson Cell Disrupter at setting #4 for 6.0 minutes at 60°C. The sample was then centrifuged for one hour at 20,000 RPM in a Sorvall RC2B centrifuge at 20^*C. The supernatant was decanted and 410ul was chromatographed over a sephadex G-100 column equilibrated with lOmM phosphate buffer, pH 7.4. The derivatized neuraminic acid (DERIV. N.A.) was then added to the liposomes for the DERIV N.A. sample and allowed to react with the MPB-PE that was already in the liposomal membrane.

These test samples were then tested in normal rats. In the rat study, five rats were used for each group. The test samples were administered intravenously to each rat and the rats' livers and spleens were removed after two hours, under seconal anesthesia, and processed for counting the radio-label. The results of the study are shown in Figure 7. The rats that received the liposomes with the synthetically-derived neuraminic acid had significantly fewer liposomes in their livers and spleens than rats receiving the control liposomes without any neuraminic acid. Syntheticallyderived neuraminic acid is B-methoxyneuraminic acid that has been derivatized according to the above specification and does not contain a glycosidic bond that is hydrolyzable by circulating endogenous enzymes, such as neuraminidase.

The rats that received the liposomes with the naturally occurring sialic acid ganglioside showed significantly lower levels of liposomes in their livers than the comparable control rats, but not as low a level of liposomes as was observed in rats receiving the liposomes with the synthetic neuraminic acid derivative. The naturally-occurring ganglioside is a molecule that exhibits a terminal sialic acid residue accompanied by a penultimate galactose group. The sialic acid residue of that ganglioside is connected to a penultimate sugar moiety by a glycosidic bond that is hydrolyzable by the enzyme neuraminidase. The spleens of the rats receiving both the synthetic neuraminic acid and the natural ganglioside were lower than the control rats.

EXAMPLE #2: AVOIDANCE OF LIVER, SPLEEN AND HEART IN NUDE MICE WITH LIPOSOMES TARGETED TO TUMORS

Three types of liposomes were prepared:

Sample A: Tumor specific antibody (SCCL-1) ; no synthetic neuraminic acid

Sample B: Tumor specific antibody (SCCL-1) ; with synthetic neuraminic acid

Sample C: Control (non-specific) antibody; no synthetic neuraminic acid

Nude mice with xenografted human Small Cell Carcinoma of the Lung (SCCL) were used. Each liposome sample A, B, and C, was subcutaneously injected into the mice. The mice were sacrificed at forty-eight hours and their various tissues were removed for analysis of the radio-label. The data are shown in Figure 8. It is clearly shown that the most effective binding to the tumor occurred with the liposomes that were both attended to SCCL-1 antibody and were marked from liver and spleen uptake with the synthetic neuraminic acid. The liposomes with the SCCL-1 antibody still did significant targeting to the tumor, but some of the liposomes were found in other tissues. The liposomes that had neither site-binding antibodies of synthetic neuraminic acid were found in significant amounts in liver, spleen, and lung.

A generic representation of naturally-occurring neuraminic acid is shown in Figure 1. Five derivatives found naturally in man are:

1. Neu 5 Ac

2. Neu 5,9 Ac²;

3. Neu 5,7,9 Ac²

4. Neu 5 Ac 9 Lt

5. Neu 5 Gc Definitions:

Neu = Neuraminic acid

Ac = acetyl - CH₃CO-

Gc = glycolyl = OHCH₂CO

Lt - lactyl - CH₃ CHOH)CO

Neuraminic acid and its above-described derivatives are found naturally in warm-blooded hosts and are known generally as sialic acid and sialic acid derivatives. So- called "GM-1" is a natural sialic acid derivative commonly used for masking liposomes from the RES. Sialic acid itself acts as a protective red blood cell component, to prevent the RES from phagocytosing the red blood cells. The use of sialic acid and its naturally-occurring deriva¬ tives for extending the in vivo circulating and binding life of liposomes, however, is limited, because endogenous enzymes circulating in the plasma, such as neuraminidase, cleave the sialic acid or its derivative from the liposome. The unmasked liposomes are then exposed to the RES, and phagocytosed. Red blood cells are likewise phagocytosed when the sialic acid is thus cleaved.

This invention addresses this cleavage problem by using a synthetic sialic acid that forms a non-hydrolyzable bond with the liposome. While not the preferred embodiment of this invention, the derivatives of natural sialic acid shown above may also be synthetically attached via a non-hydrolyzable bond by removing the acetyl group in examples #1-4 or the glycol group in example #5. The net effect of this removal is to expose a primary amino group which can be derivatized with succiniroedyl acetyl thio acetic acid to form an amide linkage (-CONH-) which is a bond that cannot be hydrolyzed by a circulating indogenous enzyme such as neuraminidan. This new series of synthetically-manipulated neuraminic acid derivatives, when attached to liposomes, provide superior masking from the RES.

The preferred embodiment, however, is the synthetic, B-methoxy form of neuraminic acid shown in Figure 2.

Claims

WHAT IS CLAIMED IS:

1. A composition of matter for in vivo administration of therapeutic or diagnostic agents, comprising: a lipid membrane structure in the form of a liposome or vesicle: a second component which is a synthetically-derived molecule that prevents recognition of the liposome or vesicle by the RES and which cannot be cleaved from the liposome or vesicle by the action of endogenous enzymes; and a third component which is a molecule that binds the liposome or vesicle to a specific site in the body and which can be present for site-specific delivery or absent for non-specific delivery of the therapeutic or diagnostic agents in vivo.

2. A composition of matter for internal administration in the therapeutic or diagnostic treatment of a warm-blooded animal comprising: a first component which comprises lipid membrane structures in the form or vesicles of liposomes; a second component which is a molecule attached to the vesicle or liposome wall and selected from the class consisting of those chemicals which are classed biologically as synthetically derived molecules that prevent phagocytosis of the vesicle or liposome by the body's RES system and which cannot be cleaved from the vesicle or liposome by endogenous enzymes circulating in plasma; and a third component which is a molecule attached to the vesicle or liposome wall and selected from the class consisting of those chemicals which are classed biologically as molecules that bind or are bound to, specific sites in the body.

3. A composition of matter as defined in claim 2, wherein the second component thereof is a synthetically-derived neuraminic acid.

4. A composition of matter as defined in claim 3, wherein the neuraminic acid has an acetyl group on carbon 5.

5. A composition of matter as defined in claim 3, wherein the neuraminic acid has a methoxy group on carbon 2.

6. A composition of matter as defined in claim 3, wherein the neuraminic acid has an acetyl group attached to the nitrogen on carbon 5.

7. A composition of matter as defined in claim 3, wherein the neuraminic acid has an acetyl group attached to the nitrogen on carbon 5, and to the oxygen on carbon 9.

8. A composition of matter as defined in claim 3, wherein the neuraminic acid has an acetyl group attached to the nitrogen on carbon 5, and to the oxygen on carbon 7 and to the oxygen on carbon 9.

9. A composition of matter as defined in claim 3, wherein the neuraminic acid has an acetyl group attached to the nitrogen on carbon 5, and a lactyl group attached to the oxygen on carbon 9.

10. A composition of matter as defined in claim 3, wherein the neuraminic acid has a glycolyl group attached to the nitrogen on carbon 5.

11. A liposome or vesicle delivery system consisting of a phospholipid membrane which includes a site-binding molecule and a synthetic neuraminic acid component, wherein said neuraminic acid is connected to the liposome or vesicle by a covalent chemical bond which is not hydrolysed by endogenous enzymes in the blood of a warm- blooded animal.

12. A liposome or vesicle delivery system for preferential delivery to a specified site within the body of a warm-blooded host, said system consisting essentially of a phospholipid membrane which includes a monoclonal antibody molecule for binding to said specific site, and with a synthetic neuraminic acid component wherein said acid is connected to the liposome by a covalent chemical bond which is not hydrolyzed by endogenous enzymes int he blood of a warm blooded animal, said delivery system providing enhanced delivery of said phospholipid membrane and said membrane's cargo to said specific site.

13. A composition of matter for internal administration in the therapeutic or diagnostic treatment of a warm blooded animal comprising: a first component which comprises lipid membrane structures in the form of vesicles or liposomes; and a second component which is a molecule attached to the vesicle or liposome wall and selected from the class consisting of those chemicals which are classed biologically as synthetically-derived molecules that prevent phagocytosis of the vesicle or liposome by the body's reticuloendothelial (RES) system and which cannot be cleaved from the vesicle or liposome by endogenous enzymes in the blood of the host.